Department of Neurology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Department of Pediatrics, UMass-Chan Baystate, 759 Chestnut St, Springfield, MA, 01199, USA.
J Med Case Rep. 2023 Feb 24;17(1):64. doi: 10.1186/s13256-023-03779-3.
Bamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization.
We report on a 5-year-old white male with preexisting conditions, predisposing him to severe disease, who developed hypoxia and flushing 3 minutes into his infusion, thus meeting the criteria for anaphylaxis.
We believe this patient developed either an immunoglobulin E-mediated anaphylactic or a non-immunoglobulin E-mediated anaphylactoid reaction to bamlanivimab and etesevimab, which is an important possibility to consider on administration.
巴利昔单抗和依特司韦单抗已被授权用于 12 岁以下有从轻/中度 2019 冠状病毒病进展为严重疾病和住院风险的儿童。
我们报告了一例 5 岁白人男性，存在使他易患严重疾病的基础疾病，他在输注 3 分钟后出现缺氧和潮红，因此符合过敏反应的标准。
我们认为该患者对巴利昔单抗和依特司韦单抗发生了免疫球蛋白 E 介导的过敏反应或非免疫球蛋白 E 介导的过敏样反应，这是在给药时需要考虑的一个重要可能性。
